Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported...
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative...
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024 Detailed top-line...
Ipsen – Half year statement – 2023 12 31 Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt...
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.